Epigenetic Biomarker and Uses Therefor Reading the Clusters in DNA's Chemical Tags to Help Detect Cancer

This patent describes an epigenetic biomarker based on the way chemical tags called methyl groups cluster along DNA, and methods that use the unusual physical behaviour of this clustered DNA to help detect the likely presence of cancer.

The Problem

Cells control which genes are switched on partly through DNA methylation, the addition of small chemical tags to DNA without changing the underlying genetic code. Cancer cells often show a distinctive pattern: methyl tags become concentrated in tight clusters in some regions. Detecting these patterns usually involves complex chemical processing and sequencing, which can be slow, costly and demanding to run at scale. A simpler, faster way to flag the abnormal methylation signature of cancer would be valuable for screening and diagnosis, especially from easily collected samples.

What This Invention Does

The patent discloses that clustered methylated genomic DNA can self-assemble into complexes with distinct physical and chemical properties compared with DNA that lacks such clusters. In other words, when the methyl tags bunch together, the DNA starts to behave differently in measurable physical ways, such as how it interacts with surfaces or in solution. The invention provides methods, systems, compositions and kits that take advantage of these properties to detect clustered methylated DNA, including to estimate the likelihood that cancer is present. Because the readout relies on a physical signature rather than full sequencing, it points toward simpler and quicker tests, the kind of approach that fits well with the goal of a liquid biopsy.

Key Features

• Cluster-based biomarker. The marker is the clustering of methyl tags along genomic DNA, a signature linked to cancer.
• Physical-property readout. Detection exploits the distinct physicochemical behaviour of clustered methylated DNA.
• Self-assembly effect. Clustered methylated DNA can form complexes that differ from unclustered DNA.
• Complete toolkit. The claims cover methods, systems, compositions and kits for detection.
• Cancer-likelihood estimation. The approach is aimed at determining the likely presence of cancer.

Who Is Behind It

The applicant is The University of Queensland, a leading Australian research university. The named inventors are Abu Sina, Laura Garcia Carrascosa and Matt Trau, a research group well known for work on rapid cancer-detection technologies. The application is a divisional of an earlier University of Queensland filing.

Why It Matters

Simpler, faster cancer detection has enormous public health value, and approaches that read a physical signature of abnormal methylation could lower the cost and complexity of testing. As an Australian university invention, protecting it locally supports commercialisation, licensing and partnerships built on home-grown research. It is a strong example of fundamental biomarker science moving toward practical diagnostics.

Related Concepts

• Epigenetics – the study of gene control beyond the DNA sequence itself.
• DNA methylation – the chemical tagging at the centre of this biomarker.
• Liquid biopsy – the kind of simple, sample-based testing this enables.
• Biomarker – a measurable signal of a biological state such as disease.
• Cancer – the condition the test is designed to help detect.

---

AU 2026201905 was published in the Australian Official Journal of Patents on 2 April 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.